KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Cash (2017 - 2025)

Historic Change in Cash for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $154.7 million.

  • Amneal Pharmaceuticals' Change in Cash rose 43871.46% to $154.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.1 million, marking a year-over-year increase of 102725.06%. This contributed to the annual value of $19.3 million for FY2024, which is 6976.68% down from last year.
  • Amneal Pharmaceuticals' Change in Cash amounted to $154.7 million in Q3 2025, which was up 43871.46% from $15.3 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Change in Cash peaked at $154.7 million during Q3 2025, and registered a low of -$172.7 million during Q2 2021.
  • For the 5-year period, Amneal Pharmaceuticals' Change in Cash averaged around -$5.7 million, with its median value being -$2.3 million (2022).
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Change in Cash crashed by 72824.09% in 2023, and later soared by 104500.0% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Change in Cash (Quarter) stood at -$53.9 million in 2021, then dropped by 12.59% to -$60.7 million in 2022, then surged by 105.77% to $3.5 million in 2023, then skyrocketed by 1045.0% to $40.1 million in 2024, then skyrocketed by 286.11% to $154.7 million in 2025.
  • Its last three reported values are $154.7 million in Q3 2025, $15.3 million for Q2 2025, and -$50.0 million during Q1 2025.